New analysis from a phase 3 trial reports that oral, once-daily siponimod (BAF312) consistently reduced disability progression in patients with secondary progressive multiple sclerosis.
John Giannouris, vice president, Specialty Pharmacy Services, ValueCentric, discusses the data customers should be asking for from a specialty pharmacy.
Top news of the week from Specialty Pharmacy Times.